Corbus Pharmaceuticals Holdings, Inc. (CRBP)
NASDAQ: CRBP · Real-Time Price · USD
9.55
+1.54 (19.23%)
At close: Mar 9, 2026, 4:00 PM EDT
9.57
+0.02 (0.21%)
After-hours: Mar 9, 2026, 4:26 PM EDT
CRBP Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | - | - | - | - | 0.88 | |
| Revenue Growth (YoY) | - | - | - | - | -77.61% | |
| Cost of Revenue | - | 32.22 | 31.17 | 16.14 | 36.45 | |
| Gross Profit | - | -32.22 | -31.17 | -16.14 | -35.56 | |
| Selling, General & Admin | 15.22 | 16.5 | 13.91 | 18.7 | 20.43 | |
| Research & Development | 70.1 | - | - | - | - | |
| Operating Expenses | 85.31 | 16.5 | 13.91 | 18.7 | 20.43 | |
| Operating Income | -85.31 | -48.72 | -45.08 | -34.84 | -55.99 | |
| Interest Expense | - | -1.87 | -3.86 | -3.1 | -2.71 | |
| Interest & Investment Income | 5.53 | 6.31 | 1.64 | 0.96 | 0.88 | |
| Currency Exchange Gain (Loss) | - | - | - | -0.43 | -0.38 | |
| Other Non Operating Income (Expenses) | 1.24 | 4.07 | 2.7 | 0.05 | 12.56 | |
| EBT Excluding Unusual Items | -78.54 | -40.21 | -44.6 | -37.35 | -45.64 | |
| Legal Settlements | - | - | - | -5 | - | |
| Pretax Income | -78.54 | -40.21 | -44.6 | -42.35 | -45.64 | |
| Net Income | -78.54 | -40.21 | -44.6 | -42.35 | -45.64 | |
| Net Income to Common | -78.54 | -40.21 | -44.6 | -42.35 | -45.64 | |
| Shares Outstanding (Basic) | 13 | 11 | 4 | 4 | 4 | |
| Shares Outstanding (Diluted) | 13 | 11 | 4 | 4 | 4 | |
| Shares Change (YoY) | 22.00% | 152.23% | 3.76% | 1.85% | 57.23% | |
| EPS (Basic) | -5.90 | -3.68 | -10.31 | -10.15 | -11.15 | |
| EPS (Diluted) | -5.90 | -3.68 | -10.31 | -10.15 | -11.15 | |
| Free Cash Flow | - | -41.79 | -36.1 | -37.56 | -48.24 | |
| Free Cash Flow Per Share | - | -3.83 | -8.34 | -9.01 | -11.78 | |
| Operating Margin | - | - | - | - | -6350.09% | |
| Profit Margin | - | - | - | - | -5176.38% | |
| Free Cash Flow Margin | - | - | - | - | -5470.98% | |
| EBITDA | -85.06 | -48.13 | -44.44 | -34.07 | -54.99 | |
| D&A For EBITDA | 0.25 | 0.59 | 0.64 | 0.76 | 1 | |
| EBIT | -85.31 | -48.72 | -45.08 | -34.84 | -55.99 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.